Targeted Next-Gen Sequencing for TB
The Advanced Diagnostic Laboratories at National Jewish Health has extensive experience diagnosing non-tuberculous mycobacteria (NTM) and tuberculosis (TB), dating back to our roots as a tuberculosis hospital in 1899. As our most recent enhancement to our diagnostic testing lineup for mycobacterial diseases, we now offer targeted next-generation sequencing (tNGS) testing for TB and MTBC speciation and antibiotic resistance.
About tNGS for TB
Targeted next-generation sequencing (tNGS) offers a number of advantages for practitioners for cutting-edge NTM and TB identification:
- tNGS can be run directly from sputum samples
- 156 mycobacterial species and subspecies identified with as few as 100-1000 mycobacterial genomes present
- Resistance to 13 antibiotics tested from 18 genes, including bedaquiline resistance
- 1-3 week turnaround time for results, as compared to 2-3 months for phenotypic testing
Our Expertise
National Jewish Health Advanced Diagnostic Laboratories is recognized internationally as a leading diagnostic laboratory for TB, NTM and other acid-fast organisms.
- CAP, CLIA and ISO 15189SM accredited
- Full speciation and subspeciation of TB and NTM
- Comprehensive menu of susceptibility testing, including drugs not commonly tested elsewhere
How to Order
Call 303.398.1420 or email padillab@njhealth.org to speak with our business development team about how we can partner to meet your testing needs.